1.
Derex L, Nighoghossian N: Intracerebral haemorrhage after thrombolysis for acute ischaemic
stroke: an update. Journal of neurology, neurosurgery, and psychiatry. 2008; 79(10):1093-99.
2.
Karaszewski B, Houlden H, Smith EE, Markus HS, Charidimou A, Levi C, Werring DJ: What
causes intracerebral bleeding after thrombolysis for acute ischaemic stroke? Recent
insights into mechanisms and potential biomarkers. Journal of neurology, neurosurgery,
and psychiatry .2015; 86(10):1127-36.
3.
Yaghi S, Eisenberger A, Willey JZ: Symptomatic intracerebral hemorrhage in acute ischemic
stroke after thrombolysis with intravenous recombinant tissue plasminogen activator:
a review of natural history and treatment. JAMA neurology. 2014; 71(9):1181-85.
4.
Adams HP, Jr., del Zoppo G, Alberts MJ, Bhatt DL, Brass L, Furlan A, Grubb RL, Higashida
RT, Jauch EC, Kidwell C et al: Guidelines for the early management of adults with
ischemic stroke: a guideline from the American Heart Association/American Stroke Association
Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention
Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes
in Research Interdisciplinary Working Groups: the American Academy of Neurology affirms
the value of this guideline as an educational tool for neurologists. Stroke .2007;
38(5):1655-11.
5.
Higashida RT, Furlan AJ, Roberts H, Tomsick T, Connors B, Barr J, Dillon W, Warach
S, Broderick J, Tilley B et al: Trial design and reporting standards for intra-arterial
cerebral thrombolysis for acute ischemic stroke. Stroke .2003; 34(8):e109-37.
6.
Tissue plasminogen activator for acute ischemic stroke. The New England journal of
medicine. 1995; 333(24):1581-87.
7.
Fiorelli M, Bastianello S, von Kummer R, del Zoppo GJ, Larrue V, Lesaffre E, Ringleb
AP, Lorenzano S, Manelfe C, Bozzao L: Hemorrhagic transformation within 36 hours of
a cerebral infarct: relationships with early clinical deterioration and 3-month outcome
in the European Cooperative Acute Stroke Study I (ECASS I) cohort. Stroke. 1999; 30(11):2280-84.
8.
Hacke W, Kaste M, Fieschi C, von Kummer R, Davalos A, Meier D, Larrue V, Bluhmki E,
Davis S, Donnan G et al: Randomised double-blind placebo-controlled trial of thrombolytic
therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian
Acute Stroke Study Investigators. Lancet .1998; 352(9136):1245-51.
9.
Hacke W, Kaste M, Bluhmki E, Brozman M, Dávalos A, Guidetti D, Larrue V, Lees K, Medeghri
Z, Machnig T et al: Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic
stroke. N Engl J Med. 2008; 359(13):1317-29.
10.
Molina CA, Alvarez-Sabin J, Montaner J, Abilleira S, Arenillas JF, Coscojuela P, Romero
F, Codina A: Thrombolysis-related hemorrhagic infarction: a marker of early reperfusion,
reduced infarct size, and improved outcome in patients with proximal middle cerebral
artery occlusion. Stroke. 2002; 33(6):1551-56.
11.
Hacke W, Donnan G, Fieschi C, Kaste M, von Kummer R, Broderick JP, Brott T, Frankel
M, Grotta JC, Haley EC, Jr. et al: Association of outcome with early stroke treatment:
pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet. 2004; 363(9411):768-74.
12.
Berger C, Fiorelli M, Steiner T, Schabitz WR, Bozzao L, Bluhmki E, Hacke W, von Kummer
R: Hemorrhagic transformation of ischemic brain tissue: asymptomatic or symptomatic?
Stroke. 2001; 32(6):1330-35.